What’s new

• The company released the full transcript of its Q4 and FY26 earnings call.
• Management reiterated its FY27 revenue growth target of 15%.
• EBITDA margins are expected to stabilize at 33% with a planned ₹70 cr capex.

Why it matters

The transcript is a routine record of a call that already occurred. It contains no price-sensitive surprises or new strategic shifts. Investors should treat the document as a record of prior disclosures rather than a source of new information.

What we’re watching

• Actual EBITDA margin performance against the 33% target.
• Deployment of the ₹70 cr capex budget throughout FY27.
• Quarterly revenue growth relative to the 15% annual guidance.

The full read

Suraksha Diagnostic released the transcript for its Q4 and FY26 earnings call. The document confirms guidance already shared with the market, including a 15% revenue growth target for FY27 and an expected EBITDA margin stabilization of 33%. The company also reaffirmed its ₹70 crore capex plan for the coming year.

It contains no new material information.

Because the transcript covers a call that has already taken place, it provides no price-sensitive updates. It is a formal record of management's commentary rather than a source of fresh insight. Investors should rely on the previously disclosed results and guidance, as this filing contains no deviations from that established outlook.

Primary source: BSE · NSE

What’s new

• Revenue growth target drops to 15% from 22.5% in FY26.
• Management targets a 33% EBITDA margin, up from 31.5% last year.
• Company plans to open 14 new centres with ₹70 cr in capex.

Why it matters

The company’s sudden dismissal of patient volume as a core metric leaves shareholders guessing about how it tracks success. Re-entering public-private partnerships after previous denials suggests a lack of clarity in long-term goals.

What we’re watching

• Whether the new centres hit the targeted 33% EBITDA margin.
• Future profitability disclosures on public-private contracts.
• Management’s rationale for ignoring patient volume in upcoming results.

The full read

Suraksha Diagnostic enters FY27 with a more conservative outlook. Management projected 15% revenue growth for the year, a drop from the 22.5% expansion recorded in FY26. To hit their 33% EBITDA margin goal, the firm must lift returns by 150 basis points from last year’s 31.5% print. A ₹70 crore capex plan to build 14 new centres is the engine for this goal.

Then the mood soured.

Management dismissed patient volume as a primary performance metric, despite using it as a key yardstick in previous quarters. The company also signaled an appetite for public-private partnership contracts, contradicting earlier statements that it would avoid such agreements. The market is left with a firm that is growing slower and changing its playbook mid-stream. It is an uncomfortable shift.

Primary source: BSE · NSE

What’s new

• Q4 PAT fell 14.1% despite a 24.7% revenue jump, showing margin pressure.
• Full-year PAT grew only 1.4% on 22.5% revenue growth for FY26.
• EBITDA margin compressed to 31.8% for the full year from 33.8%.

Why it matters

Suraksha is spending to grow, but the cost of adding new centres is currently outpacing the profit they generate. Revenue is scaling, but the earnings power per rupee of sales is shrinking. The results confirm the margin hit the board flagged earlier.

What we’re watching

• Whether new centres begin contributing positively to margins in H1 FY27.
• If the revenue growth rate can be sustained at >20%.
• Management's commentary on the timeline for margin recovery.

The full read

Suraksha Diagnostic grew revenue by 22.5% for FY26, but the profit needle barely moved. PAT increased just 1.4% for the year, and actually fell 14.1% in Q4. The problem is clear: EBITDA margins slipped to 31.8% from 33.8% as the chain expanded its network. The spending is for growth, but it's currently more expensive than the revenue it brings in. This is a classic expansion squeeze. The press release itself is routine, rehashing numbers from the board meeting, but it confirms the operational profile: top-line momentum is strong, but the earnings quality is deteriorating in the short term. The open question is when these new centres start paying their way.

Primary source: BSE · NSE

What’s new

• Standalone FY26 revenue reached ₹300.68 cr, up 20.7% over the prior year.
• Profit after tax edged up 1.9% to ₹34.06 cr, signaling margin pressure.
• The board approved a maiden dividend of ₹0.50 per share.

Why it matters

Top-line growth of 20.7% failed to reach the bottom line, with profit growth crawling at 1.9%. This reflects significant margin compression during the year. The dividend payout is a gesture of confidence, yet the underlying profitability trend requires closer scrutiny.

What we’re watching

• Whether margins rebound in the coming quarters.
• Management commentary on the cost pressures affecting profitability.
• The sustainability of the current dividend policy.

The full read

Suraksha Diagnostic booked standalone revenue of ₹300.68 crore for FY26, representing a 20.7% increase over the prior year. The gains at the top line, however, did not carry through to profitability. Profit after tax rose only 1.9% to ₹34.06 crore, which indicates clear margin compression as operating costs outpaced growth. The board attempted to offset the sentiment by recommending a dividend of ₹0.50 per share, a move that provides a 25% payout against no dividend in the previous year. Routine housekeeping matters, including auditor appointments, filled out the remainder of the disclosure. With no material surprises, these results settle into a familiar pattern for the diagnostic sector: high growth remains the objective, but managing the cost of that growth is the primary struggle.

Primary source: BSE · NSE

What’s new

• FY26 standalone revenue from operations grew 20.7% to ₹300.68 cr.
• Profit after tax rose just 1.9% to ₹34.06 cr, with growth lagging far behind the top line.
• Board recommended a ₹0.50 per share dividend, up from zero a year ago on a standalone basis.

Why it matters

Suraksha is growing revenue at a decent clip, but the earnings follow-through is weak. A 1.9% profit increase on 20.7% revenue growth means costs expanded almost as fast as sales, leaving little for the bottom line. The ₹0.50 dividend is nominal.

What we’re watching

• FY27 margin trajectory — whether cost growth can be reined in as revenue scales.
• Outcome of the step-down subsidiary dispute mentioned in disclosures.
• Any update on the Fetomat Wellness acquisition integration.

The full read

Suraksha Diagnostic's top line is growing. Its bottom line is not. The company grew standalone revenue by 20.7% in FY26 to ₹300.68 crore. Profit after tax rose just 1.9% to ₹34.06 crore. That margin squeeze is the headline. The board rewarded shareholders with a dividend of ₹0.50 per share, the first on a standalone basis in two years. It's a token. The filing also touches on the Fetomat Wellness acquisition and a step-down subsidiary dispute, both previously disclosed. The numbers themselves were anticipated. The new data point is how little of the revenue growth flowed to profit.

Primary source: BSE · NSE

What’s new

• Standalone revenue grew 20.7% to ₹300.68 crore for FY26.
• Profit after tax rose only 1.9% to ₹34.06 crore despite the top-line jump.
• Board recommended a ₹0.50 per-share dividend, returning to payouts after a one-year gap.

Why it matters

The gap between a 21% revenue rise and a 2% profit rise is the story. Suraksha grew the top line, but costs ate almost all of it. The dividend resumption is a gesture, but the payout ratio is thin. The audit opinion is clean.

What we’re watching

• What drove the margin compression in FY26.
• Whether the Fetomat Wellness acquisition adds to the cost base in FY27.
• If the dividend is sustainable given the flat profit trajectory.

The full read

Suraksha Diagnostic's FY26 numbers tell a split story. Standalone revenue climbed 20.7% to ₹300.68 crore, but profit after tax barely budged, rising just 1.9% to ₹34.06 crore. The margin got squeezed. To its credit, the board is resuming a dividend of ₹0.50 per share after paying nothing last year, but the payout is small against the profit base. The audit opinion is clean, and the filing includes routine notes on the Fetomat Wellness acquisition and a subsidiary dispute. This is a standard annual results filing, backward-looking and likely anticipated by the market.

Primary source: BSE · NSE